Chemomab Therapeutics (CMMB) Tops Q3 EPS by 7c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q3 EPS of $0.01, $0.07 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Bath & Body Works rises as Citi upgrades stock ahead of earnings
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business